Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

PharMerica to Pay $31.5 Million to Settle Lawsuit Alleging Violations of Controlled Substances Act And False Claims Act
  • USA - English


News provided by

Cross Law Firm

May 15, 2015, 14:10 ET

Share this article

Share toX

Share this article

Share toX

Cross Law Firm
Cross Law Firm

Milwaukee, Wisconsin, May 15, 2015. (PRWEB) May 15, 2015 -- Six years after Jenny Denk Buth’s False Claims Act case was filed under seal in Milwaukee, Wisconsin by her attorney, Nola J. Hitchcock Cross of Cross Law Firm, PharMerica Corporation has agreed to pay the United States $31.5 million to resolve her lawsuit., in which the government subsequently joined, alleging that PharMerica submitted false claims to Medicare for drugs dispensed without valid prescriptions in violation of the Controlled Substances Act. The Justice Department announced the settlement late yesterday afternoon.

“Blowing the whistle can be very rewarding,” said Attorney Hitchcock Cross, “both financially and ethically.”

Post this

PharMerica contracts with nursing homes and skilled nursing facilities to dispense medications to their residents, most of whom are Medicare beneficiaries. Many of the medications dispensed by PharMerica are Schedule II drugs regulated by the Controlled Substances Act, such as oxycodone and fentanyl, that are tightly controlled because they can cause significant harm if used improperly and they have been found to have a high potential for abuse.

After investigation, the government filed a complaint in intervention with Buth’s lawsuit in Milwaukee, Wisconsin. The government’s complaint alleged that PharMerica’s conduct violated the Controlled Substances Act by dispensing Controlled II drugs without confirming that a physician had first made a medical judgment as to whether the narcotics were medically necessary for the Medicare beneficiaries who were receiving them in nursing homes and skilled nursing facilities. PharMerica has agreed to pay $8 million to resolve these allegations.

In addition, PharMerica has agreed to pay $23.5 million to resolve allegations in the government’s complaint in intervention to the effect that PharMerica violated the False Claims Act by knowingly causing the submission of false claims to Medicare Part D for improperly dispensed Schedule II drugs.

The case was originally filed by Buth, a pharmacist formerly employed by PharMerica as its Pharmacy Operations Manager in Pewaukee, Wisconsin. The False Claims Act authorizes private parties to sue on behalf of the United States and to receive a portion of any recovery, generally between 15% to 25% if the government intervenes, and up to 30% if the government does not intervene. Buth will receive more than $4.3 million as her share of the settlement with the United States. In addition, she has separately settled her claim that she was fired in conjunction with her attempts to stop the alleged false claims.

“Blowing the whistle can be very rewarding,” said Attorney Hitchcock Cross, “both financially and ethically.” When Buth blew the whistle on PharMerica Corporation by filing a False Claims Act case under seal six years ago, she did so with a motivation of protecting nursing home and skilled nursing facility residents and stopping violations of the Controlled Substance Act, said Hitchcock Cross.

As a new pharmacist, Buth had a heightened concern for the elderly and disabled population who were the primary recipients of these controlled narcotics. She initially went to the Drug Enforcement Administration about her concerns and later came to Cross Law Firm which filed a False Claims Act claim for her. The Act, often dubbed the “Lincoln Law” since it dates back to fraud committed during the Civil War, allows “Relators” to file claims on behalf of the United States government for false claims submitted to and paid by the government. About 30 states, including Wisconsin, also have false claims acts.

The case is particularly significant both because it addresses the Controlled Substances Act and because it claims damages sustained when claims are submitted under Medicare Part D.

“It has been a long six years and a terrific amount of work by the Department of Justice, the U.S. Attorneys’ office and our law firm, but both the public and our client are big winners financially and protections will be in place for vulnerable Medicare recipients ,” said Hitchcock Cross. She emphasized that persons with knowledge of fraud against the public should not hesitate to blow the whistle by filing False Claims Act or other whistle-blower reward claim. “The rewards can be enormous,” Hitchcock Cross explained.

Buth is particularly gratified, according to her attorney, because, in addition to the financial settlement, PharMerica Corporation has entered into a Corporate Integrity Agreement with the government. The “CIA” as it is called, requires PharMerica to implement internal compliance reforms and, for the next five years, to submit its claims for Medicare payments for independent review.

Attorney Hitchcock Cross praises the efforts and keen analysis of Assistant U.S. Attorney Stacy Gerber Ward in the U.S. Attorney’s Office of the Eastern District of Wisconsin and trial attorney Jeff Wertkin in the Department of Justice in Washington, D.C., as well as the agents of the HHS-OIG and the DEA.

The claims resolved by the settlement are allegations only; there has been no determination of liability.
The lawsuit is captioned U.S. ex rel. Denk v. PharMerica Corp., No. 09-cv-720 (E.D. Wis.).

Nola Hitchcock Cross is the founder of Cross Law Firm that has earned a national reputation for successful representation of whistleblowers in federal courts across the United States. The firm currently has three nation-wide False Claims Act cases out from seal and in litigation, two in healthcare and one in defense contracting. The firm has obtained several prior large recoveries for their clients and the taxpayers.

For more information about the firm’s attorneys, FCA settlements and FCA experience, see http://www.crosslawfirm.com with offices in Milwaukee and Waukesha, Wisconsin and satellite offices in Chicago and Wausau, WI.

MEDIA CONTACTS: Nola J. Hitchcock Cross, Cross Law Firm, 845 N. 11th Street, Milwaukee, WI 53233; njhcross(at)crosslawfirm(dot)com 414-224-0000 http://www.crosslawfirm.com

Nola Cross, Cross Law Firm, +1 414-224-0000 Ext: 104, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.